If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ™ (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should Zepbound™ (tirzepatide) doses be increased?
Tirzepatide should be initiated at 2.5 mg subcutaneously once weekly and increased in 2.5 mg increments every 4 weeks until target dose is achieved, up to a maximum dose of 15 mg.
See important safety information, including boxed warning, in the attached prescribing information.
Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide‑1 (GLP‑1) receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of
- 30 kg/m2 or greater (obesity) or
- 27 kg/m2 or greater (overweight) with at least 1 weight-related comorbid condition (eg, hypertension, dyslipidemia, type 2 diabetes [T2D], obstructive sleep apnea, or cardiovascular disease).1
The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for chronic weight management.1
After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.1
The dosage may be increased in 2.5 mg increments, after at least 4 weeks on the current dose.1
The recommended maintenance dosages of tirzepatide in adults are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.1
Consider treatment response and tolerability when selecting the maintenance dosage. If patients do not tolerate a maintenance dosage, consider a lower maintenance dosage.1
The maximum dosage of tirzepatide is 15 mg injected subcutaneously once weekly.1
Prior to initiation, patients and caregivers must be trained on proper injection technique and how to set the syringe for appropriate dose administration.1
- once weekly
- any time of day, and
- with or without food.1
Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm and injection sites should be rotated with each dose.1
Enclosed Prescribing Information
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2023.
2le Roux CW, Zhang S, Aronne LJ, et al. Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program. Obesity (Silver Spring). 2023;31(1):96-110. https://doi.org/10.1002/oby.23612
3Conterno E, Yuffa I, Woodward B. Eli Lilly and Company diabetes 2019 business update. Eli Lilly and Company. Published June 10, 2019. Accessed October 18, 2023. https://investor.lilly.com/static-files/a5dbe9fa-f45f-41ef-bc16-bc12be6dd606
Date of Last Review: November 08, 2023